If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Mounjaro ® (tirzepatide) injection
2.5 mg/5 mg/7.5 mg/10 mg/12.5 mg/15 mg
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
What information is available about switching to Mounjaro® (tirzepatide) for the treatment of type 2 diabetes from a glucagon-like peptide-1 (GLP-1) receptor agonist?
There are currently no data on the effects of switching between tirzepatide and a GLP-1 receptor agonist. The ongoing SURPASS-SWITCH and SURPASS-SWITCH-2 trials evaluate the safety and efficacy of tirzepatide after switching from a GLP-1 receptor agonist.
See important safety information, including boxed warning, in the attached prescribing information.
Prescribing Information Related to Dosing
Tirzepatide is a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes (T2D) for once-weekly, subcutaneous administration.1
The recommended starting dose of tirzepatide is 2.5 mg once weekly. After 4 weeks, increase the dose to 5 mg once weekly. If needed, dose increases can be made in 2.5 mg increments after a minimum of 4 weeks on the current dose. The maximum dose of tirzepatide is 15 mg once weekly.1
Switching From GLP-1 Receptor Agonist
Enclosed Prescribing Information
1Mounjaro [package insert]. Indianapolis, IN: Eli Lilly and Company; 2023.
2A study of tirzepatide (LY3298176) in adult participants with type 2 diabetes switching from dulaglutide (SURPASS-SWITCH). ClinicalTrials.gov identifier: NCT05564039. Updated October 12, 2023. Accessed October 17, 2023. https://clinicaltrials.gov/ct2/show/NCT05564039
3A study of tirzepatide (LY3298176) in adults with type 2 diabetes switching from a GLP-1 RA (SURPASS-SWITCH-2). ClinicalTrials.gov identifier: NCT05706506. Updated September 15, 2023. Accessed October 17, 2023. https://www.clinicaltrials.gov/ct2/show/NCT05706506
Date of Last Review: February 07, 2023